Advertisement

Topics

These highlights do not include all the information needed to use Olopatadine Hydrochloride Ophthalmic Solution USP safely and effectively.See full prescribing information for Olopatadine Hydrochloride Ophthalmic Solution USP. Olopatadine Hydrochloride Op | Olopatadine Hydrochloride [Apotex Corp.] | BioPortfolio

13:25 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Olopatadine hydrochloride ophthalmic solution, 0.2% is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

The recommended dose is one drop in each affected eye once a day.

Ophthalmic solution 0.2%: each ml contains 2.22 mg of olopatadine hydrochloride.

None.

5.1 For topical ocular use only. Not for injection or oral use.

5.2 Contamination of Tip and Solution

As with any eye drop, to prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.

5.3 Contact Lens Use

Patients should be advised not to wear a contact lens if their eye is red.

Olopatadine hydrochloride ophthalmic solution, 0.2% should not be used to treat contact lens related irritation.

The preservative in olopatadine hydrochloride ophthalmic solution, 0.2%, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses andwhose eyes are not red,should be instructed to wait at least ten minutes after instillingolopatadine hydrochloride ophthalmic solution, 0.2%before they insert their contact lenses.

Symptoms similar to cold syndrome and pharyngitis were reported at an incidence of approximately 10%.

The following adverse experiences have been reported in 5% or less of patients:

Ocular: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus.

Non-ocular: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion.

Some of these events were similar to the underlying disease being studied.

Teratogenic effects: Pregnancy Category C

Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 150,000 times the MROHD and rabbits treated at 400 mg/kg/day, or approximately 100,000 times the MROHD, during organogenesis showed a decrease in live fetuses. In addition, rats treated with 600 mg/kg/day of olopatadine during organogenesis showed a decrease in fetal weight. Further, rats treated with 600 mg/kg/day of olopatadine during late gestation through the lactation period showed a decrease in neonatal survival and body weight. There are, however, no adequate and well- controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when olopatadine hydrochloride ophthalmic solution, 0.2% is administered to a nursing mother.

Safety and effectiveness in pediatric patients below the age of 2 years have not been established.

No overall differences in safety and effectiveness have been observed between elderly and younger patients.

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% is a sterile ophthalmic solution containing olopatadine for topical administration to the eyes. Olopatadine hydrochloride is a white to off-white, crystalline, water-soluble powder with a molecular weight of 373.88 and a molecular formula of CHNO • HCl. The chemical structure is presented below:

 

Chemical Name: 11-[(Z)-3-(Dimethylamino) propylidene]-6-11dihydrodibenz[b,e] oxepin-2-acetic acid, hydrochloride

Each mL of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% contains: Active: 2.22 mg olopatadine hydrochloride equivalent to 2 mg olopatadine. Inactives: povidone; sodium chloride; sodium phosphate dibasic (anhydrous); edetate disodium dihydrate; benzalkonium chloride 0.01% (preservative);hydrochloric acid/sodium hydroxide (to adjust pH); and water for injection.

It has a pH of approximately 5.0 - 8.0 and an osmolality range of 260 - 320 mOsm/kg.

Olopatadine is a mast cell stabilizer and a histamine H antagonist. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.

Systemic bioavailability data upon topical ocular administration of olopatadine hydrochloride ophthalmicsolution, 0.2% are not available. Following topical ocular administration of olopatadine 0.15% ophthalmic solution in man, olopatadine was shown to have a low systemic exposure. Two studies in normal volunteers (totaling 24 subjects) dosed bilaterally with olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (< 0.5 ng/mL). Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. The elimination half-life in plasma following oral dosing was 8 to 12 hours, and elimination was predominantly through renal excretion. Approximately 60 - 70% of the dose was recovered in the urine as parent drug. Two metabolites, the mono-desmethyl and the N-oxide, were detected at low concentrations in the urine.

Olopatadine administered orally was not carcinogenic in mice and rats in doses up to 500 mg/kg/day and 200 mg/kg/day, respectively. Based on a 40 μL drop size and a 50 kg person, these doses were approximately 150,000 and 50,000 times higher than the maximum recommended ocular human dose (MROHD). No mutagenic potential was observed when olopatadine was tested in an in vitro bacterial reverse mutation (Ames) test, an in vitro mammalian chromosome aberration assay or an in vivo mouse micronucleus test. Olopatadine administered to male and female rats at oral doses of approximately 100,000 times MROHD level resulted in a slight decrease in the fertility index and reduced implantation rate; no effects on reproductive function were observed at doses of approximately 15,000 times the MROHD level.

Results from clinical studies of up to 12 weeks duration demonstrate that olopatadine ophthalmic solution 0.2% when dosed once a day is effective in the treatment of ocular itching associated with allergic conjunctivitis.

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% is supplied in a white opaque ophthalmic bottle with a white translucent ophthalmic dropper and a white opaque plastic cap in the following size:

2.5 mL fill in 5 mL bottle: NDC 60505-0586-4

Storage

Keep out of reach of children.

17.1 Topical Ophthalmic Use Only

For topical ophthalmic administration only.

17.2 Sterility of Dropper Tip

Patients should be advised to not touch dropper tip to any surface, as this may contaminate the contents.

17.3 Concomitant Use of Contact Lenses

Patients should be advised not to wear a contact lens if their eyes are red. Patients should be advised that olopatadine hydrochloride ophthalmic solution 0.2% should not be use to treat contact lens-related irritation. Patients should also be advised to remove contact lenses prior to instillation of olopatadine hydrochloride ophthalmic solution 0.2%. The preservative in olopatadine hydrochloride ophthalmic solution 0.2%, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted following administration of olopatadine hydrochloride ophthalmic solution 0.2%.

Manufactured by:

Apotex Inc.

Toronto, Ontario

Canada M9L 1T9

Manufactured for:

Apotex Corp.

Weston, FL 33326

275523

October 2016

PRINCIPAL DISPLAY PANEL - Bottle

2.5 mL Bottle

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%

Apotex Corp.

Rx Only

PRINCIPAL DISPLAY PANEL - Carton

2.5 mL Bottle Carton

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%

Apotex Corp.

Rx Only

Manufacturer

Apotex Corp.

Active Ingredients

Source

Drugs and Medications [223 Associated Drugs and Medications listed on BioPortfolio]

Olopatadine hydrochloride [apotex corp.]

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%

Olopatadine hydrochloride [preferred pharmaceuticals inc.]

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%

Olopatadine hydrochloride [a-s medication solutions]

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%

Olopatadine hydrochloride [aurobindo pharma limited]

Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% Rx Only

Olopatadine hydrochloride [cipla usa inc.]

Olopatadine Hydrochloride Ophthalmic Solution USP 0.1%

Clinical Trials [2210 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age

The purpose of the study is to assess the safety of the study drug, Patanase (Olopatadine Hydrochloride Nasal Spray 0.6%) compared to placebo (inactive substance) in children ages 2 to les...

Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis

This study compares the efficacy of Hylo-Dual (Hyaluronic acid 0.05% & Ectoine 2.0%) and Olopatadine (Olopatadine hydrochloride ophthalmic solution 0.1%) in the control of seasonal allergi...

Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)

To evaluate the efficacy of olopatadine 0.1% using the OHIO Chamber in patients with seasonal allergic conjunctivitis.

Mast-Cell Stabilizing Effects of Olopatadine

To assess the effects of olopatadine of the release of mast cell histamine

Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunct...

PubMed Articles [208 Associated PubMed Articles listed on BioPortfolio]

Olopatadine/Mometasone Combination Nasal Spray Improves Seasonal Allergic Rhinitis Symptoms in an Environmental Exposure Chamber Study.

GSP301 nasal spray is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate intended for seasonal allergic rhinitis (SAR) treatment.

Protective effects of berberine hydrochloride on DSS-induced ulcerative colitis in rats.

Berberine hydrochloride is one the effective compound among Rhizoma Coptidis, Cortex Phellodendri, and other plants. There are several clinical functions of berberine hydrochloride including anti-infl...

In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses.

A number of drug-releasing contact lenses are currently being studied to address issues inherent in eye drops as a drug delivery method. In this study, we developed epinastine hydrochloride-releasing ...

In vitro and ex vivo studies on Diltiazem hydrochloride-loaded microsponges in rectal gels for chronic anal fissures treatment.

Diltiazem hydrochloride, topically applied at 2% concentration, is considered effective for the treatment of chronic anal fissures, althought it involves several side effects among which anal pruritus...

Tramadol hydrochloride: An alternative to conventional local anaesthetics for intraoral procedures- a preliminary study.

To evaluate and compare the soft tissue anaesthesia produced by tramadol hydrochloride on gingival tissues in maxilla.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record